Clinical Importance of Filaggrin Gene Mutation for Treatment Outcome in Atopic Dermatitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01689805 |
Recruitment Status
: Unknown
Verified September 2012 by Anita Remitz, Helsinki University Central Hospital.
Recruitment status was: Recruiting
First Posted
: September 21, 2012
Last Update Posted
: September 21, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Atopic Dermatitis |
Study Type : | Observational |
Estimated Enrollment : | 800 participants |
Observational Model: | Case Control |
Time Perspective: | Prospective |
Official Title: | Do Mutations in the Filaggrin Gene Have Clinical Importance for the Treatment Outcome in Atopic Dermatitis? |
Study Start Date : | June 2011 |

Group/Cohort |
---|
Patients with atopic dermatitis |
Non-atopic controls |
- Filaggrin mutation
- Response to treatment [ Time Frame: 12 months ]
- Serum IgE [ Time Frame: 12 months ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Patients with atopic dermatitis who are followed-up at the Skin and Allergy Hospital in Helsinki for at least one year can be included in the study.
The control population consists of non-atopic persons without any other skin disease (samples for the control population are applied for from a sample collection of the National institute for health and welfare).
Inclusion Criteria (patients with atopic dermatitis):
- Age at least 18 years
- Clinical diagnosis of atopic dermatitis
- Need for follow-up at the Skin and Allergy Hospital
- Patient gives signed informed consent to participate in this study
- Patients parents and grandparents are of Finnish origin
Inclusion Criteria (Controls):
- No history of atopy or skin disease
- Age at least 18 years

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01689805
Contact: Anita Remitz, MD, PhD | +358-9-4711 | anita.remitz@hus.fi |
Finland | |
Skin and Allergy Hospital, Departments of Dermatology and Clinical Genetics | Recruiting |
Helsinki, Finland, PB 160 | |
Contact: Anita Remitz, MD, PhD anita.remitz@hus.fi | |
Principal Investigator: Anita Remitz, MD, PhD | |
Sub-Investigator: Sakari Reitamo, MD, PhD | |
Sub-Investigator: Johanna M Mandelin, MD, PhD | |
Sub-Investigator: Ville Kiiski, MD | |
Sub-Investigator: Minna Pöyhönen, MD, PhD | |
Sub-Investigator: Eveliina Salminen, MD, PhD | |
Sub-Investigator: Sirpa Kivirikko, MD, PhD |
Principal Investigator: | Anita Remitz, MD, PhD | Skin and Allergy Hospital, Helsinki University Central Hospital |
Responsible Party: | Anita Remitz, MD, PhD, Specialist in Dermatology, Helsinki University Central Hospital |
ClinicalTrials.gov Identifier: | NCT01689805 History of Changes |
Other Study ID Numbers: |
FLG-255-AR |
First Posted: | September 21, 2012 Key Record Dates |
Last Update Posted: | September 21, 2012 |
Last Verified: | September 2012 |
Keywords provided by Anita Remitz, Helsinki University Central Hospital:
Atopic dermatitis Filaggrin |
Additional relevant MeSH terms:
Dermatitis Dermatitis, Atopic Eczema Skin Diseases Skin Diseases, Genetic |
Genetic Diseases, Inborn Skin Diseases, Eczematous Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |